Wegovy for weight management: dose steps, safety and stopping
Wegovy contains semaglutide, a GLP-1 receptor agonist, and is authorised in the EU for weight management together with a reduced-calorie diet and more physical activity. It is used in adults with obesity, or with overweight and a weight-related condition, and in some adolescents. It is a prescription-only medicine. This page covers how it works, how the dose is built up, the side effects to watch for and when the treatment is not suitable.
What Wegovy is and how it differs from Ozempic and Rybelsus
Wegovy contains the active substance semaglutide. It is authorised centrally for the whole EU, and its product information is published by the European Medicines Agency. The injection is given under the skin once a week from a pre-filled pen or syringe, in strengths from 0.25 mg up to 7.2 mg. The same product information also covers Wegovy tablets, which adults take once a day.
Ozempic and Rybelsus contain the same substance but are authorised for a different purpose: their product information gives the indication as type 2 diabetes in adults whose blood sugar is not controlled well enough, not weight management. Ozempic is a weekly injection and Rybelsus a daily tablet. Our page on Ozempic and the other semaglutide medicines covers them.
Do not switch between these products on your own, and do not use two such medicines together. The product information says that semaglutide should not be combined with other GLP-1 receptor agonists, and that the effect of switching between the tablets and the injection cannot easily be predicted. A switch is the doctor's decision.
Who Wegovy is authorised for
Wegovy is always used together with a reduced-calorie diet and more physical activity, both for losing weight and for keeping it off. Section 4.1 of the product information sets out who it is for. The criteria are a frame: within it, the doctor decides whether treatment is appropriate for you, looking at your weight history, other conditions, other medicines and what you have already tried. It is not a medicine for losing weight when your weight is already in the healthy range.
| Group | Criteria in section 4.1 of the product information |
|---|---|
| Adults with obesity | Starting BMI of 30 kg/m² or more |
| Adults with overweight | Starting BMI of 27 kg/m² to under 30 kg/m², with at least one weight-related condition such as prediabetes or type 2 diabetes, high blood pressure, abnormal blood fats, obstructive sleep apnoea or cardiovascular disease |
| Adolescents aged 12 and over (injection only) | Obesity on age- and sex-specific growth charts (BMI at or above the 95th percentile) and body weight above 60 kg |
Adolescents and children
For adolescents, the product information adds a stopping rule: treatment should be stopped and re-evaluated if the BMI has not fallen by at least 5% after 12 weeks on 2.4 mg or on the highest dose tolerated. Doses above 2.4 mg a week are not recommended at this age, and safety and efficacy below the age of 12 have not been established.
The treatment of a child or adolescent belongs with a doctor who can see them in person and follow them up; our questionnaire is not a suitable route for a first assessment of that kind. What the BMI figures mean, for adults and for younger people, is explained in our guide to obesity and BMI.
How semaglutide works
Semaglutide is a GLP-1 analogue: it binds to and activates the receptor for GLP-1, a natural hormone released from the gut after a meal. That receptor is present in several areas of the brain involved in regulating appetite. In the clinical studies described in the product information, semaglutide reduced energy intake, increased feelings of fullness, and reduced hunger and the frequency and intensity of cravings.
It also lowers blood sugar when it is high, by stimulating insulin release and reducing glucagon, which is why people with diabetes need their other medicines reviewed at the start. It slows the emptying of the stomach, which can affect other medicines taken by mouth; delayed stomach emptying is itself listed among the side effects. The weight loss follows from eating less, which is why the product information pairs the medicine with diet and physical activity rather than using it on its own.
How the dose is built up
Treatment starts low and is increased in steps over 16 weeks, to reduce the likelihood of digestive side effects. The table shows the usual schedule for the weekly injection in adults, from section 4.2 of the product information and the package leaflet. Your own doses are set by the doctor, and the leaflet in your pack is the instruction to follow.
| Weeks of treatment | Weekly dose |
|---|---|
| 1 to 4 | 0.25 mg |
| 5 to 8 | 0.5 mg |
| 9 to 12 | 1 mg |
| 13 to 16 | 1.7 mg |
| From week 17 | 2.4 mg (maintenance dose) |
| From week 21, if the doctor decides | 7.2 mg, only for adults whose BMI was 30 kg/m² or more at the start of treatment |
Using the injection and missed doses
If nausea or vomiting is troublesome, the doctor may delay the next step or go back to the previous dose until the symptoms improve. If 7.2 mg brings no additional improvement in weight, the dose goes back to 2.4 mg. Adolescents follow the same steps up to 2.4 mg. The tablets have their own schedule: a daily dose that is increased in steps of at least four weeks.
The injection goes under the skin of the abdomen, thigh or upper arm, once a week at any time of day, with or without food; it is not injected into a vein or a muscle. You can change the injection day if at least 3 days have passed since the last dose. If you miss a dose and 5 days or fewer have passed, inject it as soon as you remember; if more than 5 days have passed, skip it and inject the next dose on your usual day. Do not use a double dose.
After several missed doses, the doctor may restart you at a lower dose. Never share your pen or needles with anyone else. Storage rules differ between the pen types and the tablets, so follow the leaflet in your pack. If you use more than you should, talk to a doctor straight away, and do not stop the medicine without talking to the doctor.
Common side effects
The most common side effects are digestive: nausea, vomiting, diarrhoea, constipation and stomach pain, together with headache and tiredness. The package leaflet lists them as very common and says that they are mainly seen while the dose is being increased and usually go away over time. Vomiting and diarrhoea can lead to dehydration, so drink enough fluids, especially if you have kidney problems.
Other common side effects include dizziness, a change in taste, changes in skin sensation, an inflamed stomach, reflux or heartburn, indigestion, burping, wind, bloating, hair loss (more often at 7.2 mg), reactions at the injection site and, in people with type 2 diabetes, low blood sugar. Gallstones are also common, and inflammation of the gallbladder has been reported; pain in the upper right side of the abdomen is a reason to contact a doctor, particularly when your weight is falling quickly.
Low blood sugar is mainly a risk if you also take insulin or a sulfonylurea, and the doctor may lower the dose of those medicines when you start. Warning signs listed in the leaflet include a cold sweat, cool pale skin, headache, a fast heartbeat, feeling very hungry, shakiness and confusion. The full list of side effects, with how often each one occurs, is in the leaflet for your pack.
When to get medical help straight away
Some effects need medical attention without waiting for them to settle. In an emergency, call 112.
Before any procedure under general anaesthesia or deep sedation, including a gastroscopy or colonoscopy under sedation, tell the team that you use this medicine, even if the procedure was arranged at short notice. Cases of pulmonary aspiration, where stomach contents pass into the airways, have been reported in people on GLP-1 receptor agonists undergoing general anaesthesia or deep sedation, because food can stay in the stomach for longer than expected.
- Severe, long-lasting pain in the stomach area, which may spread to the back: this can be a sign of an inflamed pancreas (acute pancreatitis). See a doctor straight away; semaglutide is stopped if pancreatitis is suspected.
- Breathing difficulty, swelling of the face, throat, arms or legs, light-headedness, a fast heartbeat, sweating or fainting: these can be signs of a severe allergic reaction and need emergency help.
- A sudden loss of vision, or eyesight that gets worse quickly, in one eye or both: contact a doctor immediately. It can be caused by a very rare eye condition, non-arteritic anterior ischaemic optic neuropathy (NAION); you may need an eye examination, and stopping the medicine is the doctor's decision.
- Severe constipation with stomach ache, bloating or vomiting: this can be a sign of a blocked bowel.
- Any change in your vision if you have diabetic eye disease: tell the doctor, because the eye disease can get worse during treatment.
Other medicines, alcohol, contraception and pregnancy
Because semaglutide delays stomach emptying, it could affect how other medicines taken by mouth are absorbed, and the product information advises caution with medicines that need to be absorbed quickly. If you take warfarin or a similar anticoagulant, your blood clotting (INR) should be checked often when you start. Tell the doctor about everything you take, including medicines bought without a prescription and supplements.
Alcohol is not listed as an interaction in the product information. It does add calories, puts extra strain on the pancreas and can make digestive side effects harder to cope with. Alcohol can also lower blood sugar some hours after drinking, and if you also take insulin or a sulfonylurea the risk of low blood sugar is higher, so discuss how much you drink with the doctor.
Semaglutide should not be used during pregnancy, and women who could become pregnant are recommended to use contraception during treatment. If you are planning a pregnancy, the medicine should be stopped at least two months beforehand, because it stays in the body for a long time; if you become pregnant, talk to the doctor straight away. Wegovy should not be used while breastfeeding.
According to its product information, semaglutide is not expected to make oral contraceptives less effective. The product information of a combined pill containing drospirenone and ethinylestradiol warns, however, that severe vomiting or diarrhoea can stop the pill being fully absorbed, in which case additional contraception is needed. Tell the doctor which method you use.
When Wegovy may not be suitable
Wegovy must not be used if you are allergic to semaglutide or to any of the other ingredients. The product information does not recommend it if you:
- use other products for weight loss
- have type 1 diabetes
- have severely reduced kidney function
- have moderately or severely reduced liver function with metabolic dysfunction-associated steatohepatitis (MASH)
- have severe heart failure
- have diabetic eye disease that is uncontrolled or may be unstable
What to tell the doctor before you start
Tell the doctor if you have had inflammation of the pancreas, or if you have slow stomach emptying (gastroparesis), inflammatory bowel disease or another serious disease of the digestive system, gallbladder disease, liver or kidney problems, an eating disorder, or a family history of rare thyroid or endocrine disease. Experience with Wegovy is limited in people aged 85 and over and in people with reduced liver function. These points do not always rule the treatment out, but they need to be raised before a prescription, not after.
Prescription status and the price at the pharmacy
In its EU product information (Annex II B), Wegovy is classified as a medicinal product subject to medical prescription, and this applies in every EU country. A pharmacy dispenses it only against a prescription, and the decision to prescribe belongs to a doctor after reviewing your medical information. The Medicines Authority states that in Malta all medicinal products are dispensed only from pharmacies. A pen offered anywhere else, for example on a website or through social media, has not come through that route and may be falsified, so do not use it.
We do not sell or supply medicines. The fee for the doctor's review is shown with the button on this page; the medicine is paid for separately at the pharmacy, and we do not quote its price. It is not an ePrescription and does not appear in myHealth; it is outside POYC and the Government Formulary List, and you pay for the medicine at the pharmacy in full. The article on what you pay for the review and for the medicine explains how the two costs relate.
How the doctor reviews a request
The Weight Loss Treatment service covers both starting and continuing treatment with this group of medicines. You answer a medical questionnaire about the medicine, your health and other medicines you take, and the doctor reviews your answers in writing. If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. There is no video call, no phone call and no live chat.
The doctor may ask for your current weight and height, recent test results or other records, and may decline. A first prescription needs clear indications and no contraindications in your answers. For some conditions, and in some individual cases, it is advisable to see a doctor in person; the doctor may recommend this.
If the doctor issues a prescription, you receive it as a PDF by email. You print it and bring it on paper to a pharmacy in Malta together with photo identification. Your prescription is issued in the standard EU cross-border format set out in Directive 2012/52/EU. A pharmacy in Malta may dispense it; the decision rests with the pharmacist. Take the prescription to a pharmacy within six months of the date on it; a prescription for an antibiotic cannot be dispensed more than ten days after its date of issue.
The fee covers the medical consultation, not the issuing of a document. If the doctor declines on medical or legal grounds, we refund the fee. If the doctor asks you for documents, you have at least 7 days to send them in and we send you a reminder; if you ask us, we agree a longer deadline. If the case still cannot be completed, we close the request, let you know and refund the fee in full.
Requests are reviewed by Damian Wojno, a doctor registered with the Polish Medical Chamber, licence no. 3211301. The doctor is not registered with the Medical Council of Malta.
Is Wegovy prescription-only in Malta?
Wegovy's EU product information classifies it as a medicinal product subject to medical prescription (Annex II B), and that classification applies in Malta as in every EU country. A pharmacy dispenses it only against a prescription, and the doctor's review of a request can end in a refusal.
What is the difference between Wegovy and Ozempic?
Both contain semaglutide. Wegovy is authorised for weight management in adults, and in adolescents aged 12 and over, who meet the criteria in its product information. Ozempic is authorised for adults with type 2 diabetes that is not controlled well enough, and its product information does not include weight management as an indication. The two are not interchangeable, and a switch is the doctor's decision.
How is the Wegovy dose increased?
The weekly injection starts at 0.25 mg and goes up every 4 weeks, through 0.5 mg, 1 mg and 1.7 mg, to the maintenance dose of 2.4 mg from week 17. For adults whose BMI was 30 kg/m² or more at the start, the doctor may increase it to 7.2 mg after at least 4 weeks on 2.4 mg. If side effects are troublesome, the next step can be delayed.
What are the most common side effects of Wegovy?
Nausea, vomiting, diarrhoea, constipation, stomach pain, headache and tiredness are very common, mainly while the dose is being increased, and they usually go away over time. Severe, long-lasting stomach pain that may spread to the back can be a sign of pancreatitis and needs a doctor straight away. The full list is in the leaflet for your pack.
What should I do if I miss a dose of Wegovy?
If 5 days or fewer have passed since the missed injection, use it as soon as you remember and then go back to your usual day. If more than 5 days have passed, skip the missed dose and inject the next one on your usual day. Do not use a double dose, and if you have missed several doses, ask the doctor before you restart.
Can I use Wegovy if I am planning a pregnancy?
No. Semaglutide should not be used during pregnancy, and the product information says that it should be stopped at least two months before a planned pregnancy. Women who could become pregnant are recommended to use contraception during treatment. If you become pregnant while using it, talk to the doctor straight away.
What happens to my weight when Wegovy is stopped?
In the clinical studies described in the product information, weight went up again after treatment ended. In a 52-week follow-up after the main 68-week trial, average weight rose in people who had stopped semaglutide, although it stayed below where they started, and in another trial weight rose steadily in people switched to placebo. Do not stop the medicine without talking to the doctor.
- EMA: Wegovy, European public assessment report
- EMA: Wegovy product information (summary of product characteristics, Annex II, package leaflets)
- EMA: Ozempic product information (section 4.1)
- EMA: Rybelsus product information (section 4.1)
- Medicines Authority: Yasmin 0.03 mg/3 mg film-coated tablets (MA639/02801)
- Medicines Authority: prescription-only medicines and dispensing from pharmacies
- Prescription and Dispensing Requirements Rules (S.L. 458.49), rule 4 (legislation.mt)
- Commission Implementing Directive 2012/52/EU on cross-border prescriptions (EUR-Lex, English)